U.S. Markets
Johnson & Johnson (JNJ) announces FDA approval of icotyde (icotrokinra) ushers in new Era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
